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Introduction
With over four million women presenting for prenatal care in the
United States annually and current recommendations to offer aneuploidy
testing to all, there is no doubt that advances in prenatal genetic testing
will have an important impact on the health and well-being of women
and their children. Translational genomic research over the past decade
has vastly increased our knowledge of human health and disease,
bringing the promise of improving the lives of patients through new
medical technology. Initially used in adult testing indications, many of
these technologies are finding a place in obstetrics as pregnant women
and their partners now have access to a vast array of fetal testing
options that dramatically influence the delivery of prenatal care. With
the development of new molecular testing modalities, fetal cells can now
be analyzed for dozens of genetic mutations in a single pass and provide
rich genomic information that would be undetectable using conventional
testing methods.1 The ability to conduct genetic tests on cell-free fetal
†
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1.

See Lauren C. Sayres & Mildred K. Cho, Cell-Free Fetal Nucleic Acid
Testing: A Review of the Technology and Its Applications, 66
Obstetrical & Gynecological Surv. 431, 438 (2011); see F. Lucy
Raymond et al., Molecular Prenatal Diagnosis: The Impact of Modern
Technologies, 30 Prenatal Diagnosis 674, 674 (2010).
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DNA in the maternal blood stream is paving the way for non-invasive
diagnostic tests to become part of routine prenatal care. Direct-toconsumer test offerings have become increasingly visible and accessible in
conjunction with these advances, expanding the avenues by which
women can obtain information about their pregnancies.2 It is not just
innovation in clinical genetics that has affected antenatal care. Parallel
advances in the fields of maternal-fetal medicine and neonatology are
also influencing how new genetic tests become incorporated into the care
of the pregnant woman, establishing new boundaries for optimizing in
utero health using genetic science.
The recent explosion of genetic science and technology has allowed
innovative approaches for identifying and treating disease to become a
clinical reality. While aimed at improving and preserving health, these
advances produce some of the most profound ethical, legal, and social
questions about how to integrate new technology into the healthcare and
lives of patients. These questions are twofold, as they pertain not only to
understanding the significance of personal genetic information but also
to how such information can and should be used to guide fundamental
choices about the self and family. Information about one’s genetic
makeup leads to a host of interlaced ethical and pragmatic ramifications
that spring from our limited understanding of how the presence of a
mutation plays out over the course of one’s life. Despite a more
sophisticated understanding of the human genome, it is striking that
many of the ethical and practical challenges of genetic testing remain
unresolved, such as the interpretation of personal risk from the
identification of a genetic mutation, the privacy and confidentiality of
genetic information, and the prediction of quality of life for those living
with disease or disability.
These existing dilemmas have magnified implications in women’s
reproductive health and prenatal genetic testing. While genomic research
has opened up new possibilities to assess fetal health, the sheer volume
of information generated by prenatal testing has amplified the
fundamental ethical, legal, and social conundrums that already exist for
genetic testing in other areas of medicine. In the context of pregnancy,
decisions regarding genetic testing of the developing fetus involve a
complex calculus based largely on conjecture and uncertainty. As in the
case of genetic testing for adults, it is necessary for the pregnant woman
to weigh the benefits of accessing genetic information about the fetus
against the disadvantages and limitations of that information. She must
consider the well-being of the unborn child and, as such, must integrate
a host of unknowns about disease severity, progression, and quality of

2.

Timothy Caulfield & Amy L. McGuire, Direct-to-Consumer Genetic
Testing: Perceptions, Problems, and Policy Responses, 63 Ann. Rev.
Med. 23, 24 (2012).
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life for her future child.3 Given the rapid advance of medical technology,
she is also faced with considering what therapies or other resources that
do not exist in the present may be available in the future that could
alleviate any pain or suffering resulting from a genetic condition. It is
based on these considerations that she must make the critical decision to
continue a pregnancy while planning for the birth of a child with a
genetic condition, to take part in an experimental procedure that may
influence neonatal outcomes, or to end the pregnancy.
Because of the special maternal-fetal dyad of pregnancy, women are
uniquely affected by fetal genetic information and the decisions this
information invites. Choices about prenatal genetic testing are often a
collaborative effort between expecting parents. Yet, due to the biology of
reproduction and pregnancy, women have a distinct role and a specific
interest in the integration of these tests into clinical practice. Although
prenatal genetic tests are conducted to assess the health of the fetus,
they are performed on the pregnant woman and, as a result, have direct
implications for her health and well-being. It is critical to recognize that
these implications extend far beyond collecting a maternal blood sample
or fetal cells though an invasive in utero procedure. The decision to
proceed with testing has the potential to produce a cascade of
downstream tests and procedures during the pregnancy to further
evaluate or manage fetal genetic findings. Additionally, as the fields of
perinatology and neonatology are advancing in conjunction with genetic
science, the decision to undergo testing may also affect intrapartum
management in the delivery suite. Finally, genetic information or
procedures conducted in response to that information may also influence
future reproductive decision-making.
Women are uniquely affected by advances in prenatal genetic tests
in another significant way. The decision to proceed with or to decline
testing is a very personal choice that weaves a woman’s most personal
values and beliefs about self, pregnancy, and parenthood into her
healthcare choices. However, these individualized choices about the
pregnancy are often influenced by factors external to her. Many of a
woman’s reproductive decisions are bound by laws, policies, clinical
practice guidelines, and public opinion about what a pregnant woman
should and can do during the pregnancy. Given the ramifications of all
of these issues, it is critical to understand how advances in genetic
technologies affect the health and lives of women.

3.

Anne Drapkin Lyerly et al., Risks, Values, and Decision Making
Surrounding Pregnancy, 109 Obstetrics & Gynecology 979, 983 (2007);
Ryan A. Harris et al., Decision Analysis of Prenatal Testing for
Chromosomal Disorders: What Do the Preferences of Pregnant Women
Tell Us?, 5 Genetic Testing 23, 29-30 (2001); Elena A. Gates,
Communicating Risk in Prenatal Genetic Testing, 49 J. Midwifery &
Women’s Health 220, 224 (2004).
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I.

The Evolution of Genetic Technologies

To understand the evolution and salience of these issues, it is
important to first understand how genetic technologies have evolved
over the past fifty years. One category of prenatal genetic testing that
has undergone important changes is the screening test. Screening tests
provide information about the chance that a fetus has Down syndrome
or other related chromosomal abnormalities.4 The advantage of screening
tests is that they are performed by drawing a sample of blood from the
mother without the use of more invasive procedures; thus, the pregnant
woman can bypass the uncommon but real risks associated with
chorionic villus sampling (CVS) and amniocentesis.5 When used as a
triage mechanism, screening tests help to determine which women might
benefit from definitive diagnostic testing, thus reducing the potential
number of iatrogenic losses of chromosomally normal fetuses that could
occur with generalized use of these procedures. Screening tests also have
limitations. One limitation is the ability of the screen to detect all
fetuses with an abnormal compliment of chromosomes, so that there is a
chance of a screen-negative result in the context of an affected fetus.
There is also the possibility of a false positive result, in which case the
screen would indicate an increased risk of a chromosomal abnormality
when the fetus has, in fact, a normal complement of chromosomes. Thus,
this information can only be used to inform decisions about further
testing.
The first screening tests were developed in the late 1980s and 1990s.
Initially, it was determined that the combination of three maternal
serum chemicals (human chorionic gonadotropin, unconjugated estriol,
and alpha-fetoprotein) conferred information about possible
abnormalities caused by extra or missing chromosomes (referred to as
“aneuploidy”).6 This test analyzing these three chemicals was known as
the Triple Screen. In the years following, the Quadruple Screen was
developed to increase detection rates with the addition of another
maternal serum marker called inhibin A. Since that time, there has been
a move towards earlier screening modalities. While the Triple and
Quadruple Screens provided fetal risk information, they could not be
4.

Deborah A. Driscoll & Susan J. Gross, Screening for Fetal Aneuploidy and
Neural Tube Defects, 11 Genetics Medicine 818, 818 (2009); Am. Coll. of
Obstetricians & Gynecologists, ACOG Practice Bulletin No. 77: Screening
for Fetal Chromosomal Abnormalities, 109 Obstetrics & Gynecology
217 passim (2007).

5.

Faris Mujezinovic & Zarko Alfirevic, Procedure-Related Complications of
Amniocentesis and Chorionic Villous Sampling: A Systematic Review, 110
Obstetrics & Gynecology 687, 687, 692 (2007).

6.

Devereux N. Saller, Jr. & Jacob A. Canick, Current Methods of Prenatal
Screening for Down Syndrome and Other Fetal Abnormalities, 51 Clinical
Obstetrics & Gynecology 24, 26-27 (2008).
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performed until after the fifteenth week of pregnancy. Thus, choices
about the pregnancy following confirmatory diagnostic testing could not
be made until well into the second trimester, a time when the choice to
continue or terminate the pregnancy may have very different
ramifications for the woman than if the decision had been made earlier
in the pregnancy. First trimester aneuploidy screening is a new screening
approach consisting of assessment of maternal serum markers in
conjunction with sonographic measurement of the back of the fetal neck
(also known as nuchal translucency).7 This new tool confers similar fetal
genetic risk information regarding Down syndrome as the Triple and
Quadruple Screen but can be performed as early as eleven weeks into
gestation.8 Timed one month earlier than its second trimester
counterparts, this new screening modality gives patients a wider range of
options over the course of their prenatal care, including immediate
diagnostic procedures in the initial weeks of pregnancy.
Important advances have also taken place in another category:
diagnostic testing. The procedures of CVS and amniocentesis were
developed in the latter half of the twentieth century as ways to directly
test fetal cells to confirm the presence or absence of a genetic condition.
Both procedures involve inserting a needle into the pregnant woman’s
uterus to access fetal or placental cells for testing. While amniocentesis
cannot be performed until the second trimester of pregnancy, CVS can
be performed in the first trimester.
The procedures of CVS and amniocentesis have changed little over
the decades since their development. What has changed, however, is the
number of testing applications that can be performed using these
procedural platforms. Initially, these diagnostic procedures were used to
conduct analysis for a single genetic mutation (e.g., cystic fibrosis) or
chromosomal abnormality (e.g., Down syndrome) at a time. The
development of multiplex testing techniques then allowed assessment for
multiple different single Mendelian mutations or fetal characteristics
(e.g., gender) simultaneously.9 Further advances in genetic science have
changed the basic paradigms of genetic conditions and shifted our
perception of diseases away from the concept of their being monogenic in
origin towards the idea that they often involve multiple genes in concert.
7.

Uma M. Reddy & Michael T. Mennuti, Incorporating First-Trimester
Down Syndrome Studies into Prenatal Screening: Executive Summary of
the National Institute of Child Health and Human Development Workshop,
107 Obstetrics & Gynecology 167, 169 (2006); Uma M. Reddy &
Ronald J. Wapner, Comparison of First and Second Trimester Aneuploidy
Risk Assessment, 50 Clinical Obstetrics & Gynecology 442, 445
(2007).

8.

Kevin Spencer, Aneuploidy Screening in the First Trimester, 145C Am. J.
Med. Genetics Part C: Seminars Med. Genetics 18, 20 (2007).

9.

See The Council on Ethical & Judicial Affairs, Am. Med. Ass'n, Multiplex
Genetic Testing, Hastings Ctr. Rep., July-Aug. 1998, at 15, 15.
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As a result, there has been a move towards incorporating microarrays
into prenatal care, allowing analysis to identify from tens to thousands
of variants during a single testing process.10 Prenatal microarray testing
is able to generate detailed genetic information that could not be
detected using standard cytogenetic techniques.
Until recently, diagnostic information about the fetus could only be
obtained through invasive procedures such as CVS and amniocentesis.
Now, non-invasive prenatal genetic diagnosis is changing conventional
paradigms about accessing and using fetal genetic information to guide
antepartum care. Performed by drawing a blood sample from the
pregnant woman, it is anticipated that non-invasive prenatal genetic
diagnosis will ultimately provide the same degree of diagnostic
information as more invasive procedures while bypassing the physical
risks to mother and fetus.11 The clinical potential for non-invasive
prenatal genetic diagnosis is great. Studies show that pregnant women
are very interested in using this new approach to prenatal genetic
testing.12 Preliminary studies also show that including the option of noninvasive prenatal genetic diagnosis increases women’s interest in and
willingness to undergo prenatal genetic testing for a number of different
conditions and also alters core beliefs about genetic testing in
pregnancy.13 Access to genetic information via a sample of maternal
blood is also likely to encourage the already growing direct-to-consumer
movement of genetic testing, which may further complicate legal, ethical,
and social ramifications. As the development of genetic, genomic, and
molecular technologies concurrently accelerates, the scope of possible in
utero investigations will drastically expand.

II. The Impact of Advancing Genomic Technologies on
Informed Decision-Making by Pregnant Women
While research in the field of genetics has opened up new
possibilities to assess fetal health, the sheer volume of information
generated by prenatal testing generates a host of dilemmas, challenges,
and questions. To date, many of these discussions have focused on the
10.

Ronald J. Wapner et al., Integration of Microarray Technology into
Prenatal Diagnosis: Counselling Issues Generated During the NICHD
Clinical Trial, 32 Prenatal Diagnosis 396, 399 (2012).

11.

Diana W. Bianchi et al. Genome-wide Fetal Aneuploidy Detection by
Maternal Plasma DNA Sequencing, 119 Obstetrics & Gynecology 890,
891, 900 (2012); Ruth M. Farrell & Patricia K. Agatisa, Preparing Patients
for First Trimester Prenatal Aneuploidy Screening: Effective Education by
Obstetric Providers Is Key (unpublished manuscript) (on file with author).

12.

Reana Tischler et al., Noninvasive Prenatal Diagnosis: Pregnant Women’s
Interest and Expected Uptake, 31 Prenatal Diagnosis 1292, 1296-97
(2011).

13.

Farrell & Agatisa, supra note 11.
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health and well-being of the expectant child and, by so doing, have
displaced considerations about the pregnant woman. Yet it is paramount
that discussions address the impact of these technologies on women’s
lives both during and after the pregnancy. This includes a discussion not
only of the scientific and medical aspects of the newest technologies but
also the expectations, moral obligations, values, and preferences
surrounding genetic testing, motherhood, and family that are placed on
women. Some of the issues are novel; they present women, healthcare
providers, scientists, and policy makers with nuanced questions about
the meaning, significance, and implications of acquiring detailed fetal
genetic information during pregnancy. In some cases, these issues can be
foreseen and, with adequate preparation, negative sequelae can be
mitigated before the technology is broadly implemented. In other cases,
the full ramifications of a new genetic technology do not become evident
until that technology has been widely integrated into patient care. What
is remarkable, however, is that still other issues have been lingering
unresolved since the earliest stages of prenatal genetic testing. Of
greatest concern, these pre-existing issues may be exacerbated by the
introduction of new tests that provide more detailed information about
the fetus.
One set of issues pertains to a woman’s ability to make informed
choices about her prenatal genetic testing options. With an expanding
array of testing options, a pregnant woman must have the resources to
make informed, value-reflective choices about her prenatal testing
options. Without a mechanism to support her access, understanding, and
considerations of this information, she is at risk for going down two
equally negative paths. In one scenario, she may proceed with a prenatal
genetic test without an adequate understanding of its indications,
limitations, and implications, leaving her grossly underprepared to
consider the outcomes of either ending the pregnancy or planning for the
birth of a child with a genetic condition. In the other case, she may
decline a test that might have otherwise been wanted because she did
not understand how genetic information can potentially optimize
outcomes for the expected child. Both scenarios can lead to weighty and
significant implications for the health and well-being of the woman in
the context of both the current pregnancy and future family building
plans.
Since the initial days of prenatal genetic testing, studies have shown
that pregnant women have struggled to make informed, value-reflective
decisions about their prenatal genetic testing choices. This trend has
been evident for both screening and diagnostic tests. What is significant
is that many of the same barriers to women’s education and decisionmaking continue to persist even with ongoing advancement in prenatal
applications of genetics. A core issue has been women’s ability to access
patient-centered information about genetic diseases and the approaches

7
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to identifying them.14 The priority for this kind of information is high
because decisions to undergo or decline prenatal genetic testing are an
individualized calculus requiring knowledge of the fetal genetic condition
in question, approaches to identify it, and post-test choices for the
pregnancy. In addition, these considerations must also incorporate
personal values about disability and illness, parenthood, and quality of
life. However, there are significant problems to the informed decisionmaking process related to pregnant women’s knowledge of prenatal
genetic testing, as the fundamental concepts associated with screening
and diagnostic testing remain elusive to many.15 Barriers associated with
a lack of health literacy and a limited understanding of the concepts of
risk and probability also have a notable effect on minorities and women
from lower educational and socioeconomic groups.16
Contemporary studies provide important insight into how these preexisting barriers will pose even greater challenges for innovative ways to
assess fetal health assessments. Using the first trimester aneuploidy
screen as a litmus test for the readiness of the healthcare field to support
women’s decision-making, it is evident that the same underlying
problems that arose with the introduction of the Triple and Quadruple
Screens continue to exist. For pregnant women, this manifests as deficits
in understanding (1) the purpose of this new test, (2) the ways in which
it differs from conventional tests, and (3) possible ways to navigate the
expanded decision tree of post-test options for the pregnancy. For
clinicians, there continue to be challenges in mobilizing adequate
resources to support the decision-making process for new tests. The
ongoing challenge for the healthcare provider to acquire and maintain
knowledge of clinical genetics is another contemporary problem. These
underlying problems stem not only from limitations of time and clinical
resources to support patient education but also from the reality that it
has become difficult for medical education to keep pace with advances in
14.

Id.; see, e.g., Miriam Kuppermann et al., Beyond Race or Ethnicity and
Socioeconomic Status: Predictors of Prenatal Testing for Down Syndrome,
107 Obstetrics & Gynecology 1087, 1096 (2006).

15.

Matthijs van den Berg et al., Informed Decision Making in the Context of
Prenatal Screening, 63 Patient Educ. & Counseling 110, 115 (2006);
Matthijs van den Berg et al., Are Pregnant Women Making Informed
Choices about Prenatal Screening?, 7 Genetics Medicine 332, 336-37
(2005); see generally Theresa M. Marteau & Elizabeth Dormandy,
Facilitating Informed Choice in Prenatal Testing: How Well Are We
Doing? 106 Am. J. Med. Genetics 185 (2001).

16.

Sandra Suther & Gebre-Egziabher Kiros, Barriers to the Use of Genetic
Testing: A Study of Racial and Ethnic Disparities, 11 Genetics Medicine
655, 661-62 (2009); B. Khoshnood et al., Women's Interpretation of an
Abnormal Result on Measurement of Fetal Nuchal Translucency and
Maternal Serum Screening for Prenatal Testing of Down Syndrome, 28
Ultrasound Obstetrics & Gynecology 242, 247 (2006).

8

Health Matrix·Volume 23·Issue 1·2013
Women and Prenatal Genetic Testing in the 21st Century

genetic science.17 In addition, although some degree of uncertainty has
been a long-standing component in choices about prenatal genetic tests,
such as questions about subsequent disease severity and impact on
quality of life, microarray testing has made uncertainty a much stronger
presence in the decision-making process. With the ability to identify
thousands of genetic variants, some with as-yet-unknown relevance for
health, women struggle to reconcile the meaning of an abnormal result
with choices about the pregnancy.18 Because the core leading medical,
ethical, and personal implications of accessing fetal genetic information
remain constant with all forms of prenatal genetic testing, these issues
must be addressed both for already established forms of testing as well
those innovative approaches positioned to be broadly integrated into
prenatal care. Without the recognition of these issues and mobilization
of resources to address them, pregnant women will be vulnerable to the
hazards of uninformed decision-making.

III. The Voluntary Nature of Decisions about
Prenatal Genetic Testing
Access to accurate, patient-centered information is only one
component of a pregnant woman’s preparedness to make informed
choices about prenatal genetic testing. Equally important is her ability
to make voluntary decisions about whether to proceed or decline forms
of testing. Discussions early in the development of prenatal genetic
testing brought attention to the voluntary nature of decision-making and
the need to ensure that women were positioned to make autonomous
choices about their testing options. Leading scholars paved the way to
examining the meanings and implications of the “good mother,”
including the expectations and obligations for or against testing placed
on her during pregnancy by healthcare professionals, society, and
17.

Sandy Suther & Patricia Goodson, Barriers to the Provision of Genetic
Services by Primary Care Physicians: A Systematic Review of the
Literature, 5 Genetics Medicine 70, 75-76 (2003); see Susan B. Trinidad
et al., Educational Needs in Genetic Medicine: Primary Care Perspectives,
11 Community Genetics 160, 160 (2008); Charles J. Macri et al.,
Implementation and Evaluation of a Genetics Curriculum to Improve
Obstetrician-gynecologist Residents' Knowledge and Skills in Genetic
Diagnosis and Counseling, 193 Am. J. Obstetrics Gynecology 1794,
1797 (2005); see Caulfield & McGuire, supra note 2, at 25.

18.

See Sean E. Lipinski et al., Uncertainty and Perceived Personal Control
Among Parents of Children with Rare Chromosome Conditions: The Role
of Genetic Counseling, 142C Am. J. Med. Genetics Part C: Seminars
Med. Genetics 232, 232 (2006); see generally R. Alta Charo & Karen H.
Rothenberg, "The Good Mother": The Limits of Reproductive
Accountability and Genetic Choice, in Women and Prenatal Testing:
Facing the Challenges of Genetic Technology 105, 105-30 (Karen
H. Rothenberg & Elizabeth J. Thompson eds., 1994).
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family.19 On the one hand, there were cautions for utilizing genetic tests,
raising the specter of eugenics and devaluing those individuals living
with illness and disease. On the other, there were warnings against
restricting a woman’s autonomy and autonomous decision-making.
Concepts of coercion and non-directive counseling are at the heart of
these discussions. While coercion is often conceptualized as overtly
directed counseling, it can also be more subtle in nature, such as when
information is withheld or biased. As decisions regarding testing during
pregnancy align closely with a woman’s personal beliefs, these
discussions also brought to light that the voluntary nature of decisions
can be eroded by healthcare providers who may not be aware of her
individual and cultural preferences about pregnancy, motherhood,
disability, and illness.
Over the past several decades, there has been a move not only to
develop tests that can generate a vast amount of genetic information
about the pregnancy but also to provide these data with the lowest risk
possible to the fetus. In response, new approaches to prenatal genetic
testing are being developed to fulfill these criteria. This new cohort of
tests reawakens interest in voluntariness in prenatal genetic testing and
provokes foundational discussions addressing women’s abilities to make
unhindered choices about their use.20 For many women, the iatrogenic
risks of CVS and amniocentesis served as a barrier to accessing fetal
genetic information. Now, the real possibility of gaining diagnostic level
information through a maternal blood draw stands to fundamentally
change the risk-benefit calculus that women undertake when considering
testing as an option. At the present, non-invasive diagnosis is emerging
as a tool to assess fetal risk for chromosomal abnormalities. However, its
potential for expanded genomic testing is great and, in the coming years,
it is expected that its techniques can be applied to search for a number
of different genetic variants simultaneously. In removing the medical
risks of diagnostic testing, it is important to safeguard the protections of
19.

See generally Barbara Katz Rothman, The Tentative Pregnancy: Then and
Now, in Women and Prenatal Testing: Facing the Challenges of
Genetic Technology 260 (Karen H. Rothenberg & Elizabeth J.
Thompson eds., 1994); see Abby Lippman, The Genetic Construction of
Prenatal Testing: Choice, Consent, or Conformity for Women?, in
Women and Prenatal Testing: Facing the Challenges of Genetic
Technology 9 (Karen H. Rothenberg & Elizabeth J. Thompson eds.,
1994); Charo & Rothenberg, supra note 18; Karen H. Rothenberg, Genetic
Accountability and Pregnant Women, 7 Women’s Health Issues 215
(1997).

20.

Zuzana Deans & Ainsley J. Newson, Should Non-Invasiveness Change
Informed Consent Procedures for Prenatal Diagnosis?, 19 Health Care
Analysis 122 (2011); see Dagmar Schmitz et al., An Offer You Can't
Refuse? Ethical Implications of Non-Invasive Prenatal Diagnosis, 10
Nature Revs. Genetics 515, 515 (2009).
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informed consent, including the voluntary aspects of a woman’s choice to
proceed with or decline testing.
Because the leading medical, ethical, and personal implications of
accessing fetal genetic information remain the same for all forms of
diagnostic testing (whether invasive or non-invasive), an important part
of the translational process will be to ensure every pregnant woman has
the resources to make informed, value-reflective choices about her
prenatal testing options. Thus, there is a need for contemporary
discussions to revisit the issues of voluntariness, to recognize issues
pertinent to women’s autonomous decision-making within the current
context of prenatal genetics, and to construct mechanisms to ensure that
pregnant women are not coerced with regards to genetic testing.

IV. Maternal-Fetal Surgery and the Changing
Calculus of Prenatal Genetic Testing
The evolution of prenatal genetic testing technology is not taking
place in a vacuum. Contemporary discussions must also consider the
discipline of obstetrics and how changes in this field have an undeniable
impact on how the ethical, legal, and social implications of prenatal
genetic tests take shape. The great majority of these procedures remain
experimental, and many more studies must be performed before they
become part of standard practice. However, the possibility and
availability of interventions to ameliorate the sequelae of a genetic
condition in utero will begin to shift how the benefits and limitations of
the available prenatal genetic tests are framed by patients and their
healthcare providers.
It is important to recognize the discordance between what can be
diagnosed in utero using genetic tests and what can be done to prevent
or mitigate the illness associated with a genetic mutation. Despite
advances in genetic science, procedures to effectively alter DNA-level
mutations to prevent disease or, in many cases, control the effects of a
genetic variant on an individual’s phenotype have yet to be developed.
Because of these limitations, pregnant women have customarily been
given two options following in utero diagnosis of a genetic condition.
One option was pregnancy termination, most often performed in the
second trimester of pregnancy after the testing process was completed.
For women who did not elect for or were unable to access abortion
services, another option was to continue the pregnancy and plan for the
birth of a child with a genetic condition.
For many women, the potential of being put in the position of
having to decide between these dichotomous outcomes was a key reason
for declining testing. Yet advances in the field of high-risk obstetrics and
fetal intervention have begun to alter the choices presented to pregnant
women. Together with the efforts to advance clinical genetics, there has
been a growing interest in interventions during pregnancy to improve
fetal and neonatal outcomes. Maternal-fetal surgeries entail conducting
surgery on the pregnant woman, procedures which entail making an
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incision in the woman’s abdomen and uterus to access the fetus. While
the risks of these procedures to fetus and mother are clearly identifiable,
their benefits overall remain unclear. Recent data about a procedure to
correct neural tube defects in utero may mark a pivotal point in how
prenatal genetic testing is presented to women. One of the functions of
screening tests is to identify the risk of neural tube defects, which are
errors in how the early nervous system takes shape. The primary
approach to management of pregnancies included heightened antepartum
surveillance and plans for intervention after birth. A recent study shows
that surgical management of a specific type of neural tube defect
(myelomeningocele) in utero may lead to improve outcomes for some
children, though more research must be conducted. However, this
procedure comes at a cost, as it presents serious medical risks to the
pregnant woman.21 Yet the mere availability of this option for those
women whose pregnancies have been diagnosed with a neural tube defect
fundamentally changes how the utility of prenatal genetic testing will be
framed.
This maternal-fetal surgery addresses just one of the thousands of
genetic conditions that can now be diagnosed in utero. The reality is
that, while the past decade has witnessed the growth of prenatal genetic
testing technology, there has not been parallel expansion of pregnant
patients’ post-testing options. As a result, pregnant women continue to
grapple with the dilemmas that come with the many ways to diagnose a
multitude of different genetic conditions while having very few proven
therapeutic options either during pregnancy or after birth. Thus, an
important part of discussions about the impact of new prenatal genetic
tests is recognizing that an expanding discordance is developing between
what can be identified in utero and current options to change outcomes
for the child. The result is a new and nuanced set of ethical, legal, and
social dilemmas for women as they face their prenatal genetic testing
options.

Conclusion
Some of the most profound, difficult, and controversial questions
regarding women, motherhood, family, children, and disability exist at
the intersection of obstetric and clinical genetics. Advances in molecular
genetics intensify of our uncertainties and, in some cases, our discomfort
with the ability of genetic technology to affect our lives and the world in
which we live. The quickly changing and increasing analytical
capabilities of genomic applications in the prenatal clinical context
invoke the need to evaluate the ethical, legal, and social implications of

21.

See N. Scott Adzick et al., A Randomized Trial of Prenatal Versus
Postnatal Repair of Myelomeningocele, 364 New Eng. J. Med. 993, 100204 (2011).
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these issues for those pregnant women in the position of considering
prenatal testing.
In 1991, the National Institutes of Health sponsored a workshop
entitled “Reproductive Genetic Testing: Impact upon Women” to begin
to address some of these core issues. Led by Elizabeth Thomson and
Karen Rothenberg, the workshop’s mission was to examine the impact of
prenatal genetic testing on the lives of women and to identify a set of
themes to guide the development and use of these technologies. This
meeting was a landmark event because it was the first of its kind to
bring together a multidisciplinary panel of experts to examine advances
in prenatal genetic testing within the context of women’s lives.
A host of events have taken place in the past twenty years that have
changed the landscape of prenatal genetic testing and the care of women
during pregnancy. As discussed here, these events have taken place not
only in genetic science and the practice of obstetrics but also in
discussions and policies about the delivery of prenatal care, women’s
reproductive rights, informed decision-making, and disability. Some of
these advances provoke new and unexplored questions about how to
integrate advances in clinical genetics into the care of pregnant women.
At the same time, other cornerstone issues associated with genetic
testing, such as defining and identifying illness and disease in addition to
the implications of fetal genetic information, remain unchanged and as
provocative today as they were twenty years ago. Given the accelerating
trajectory of clinical genetics, medical science, and surgical innovation, it
is critical to revisit how the lives of women are uniquely affected by the
newest approaches to prenatal care.
In response to this need, the Case Western Reserve University
School of Law hosted a symposium entitled, “New Technologies, New
Challenges: Women and Prenatal Genetic Testing in the 21st Century.”
The aim of the symposium was to bring together a group of leading
experts from the disciplines of bioethics, social science, clinical medicine,
law, and genetic science to identify those challenges and critically
examine how the health and lives of women are affected by the advances
taking place in the care of pregnant women. Scholars who participated in
the original 1991 conference joined in collaborative dialogue with new
leaders in the field, generating a solid foundation for understanding the
breadth and depth of these issues as they have evolved over the past
twenty years. Over the course of a day and a half, important strides
were made toward understanding the unique ways in which women’s
lives are affected by advances in genetic technology and the carryover of
these effects for children, families, and the practice of medicine. As the
emergence of new genetic technologies accelerates in the months and
years to come, it will be vital that multidisciplinary experts continue to
engage in examining the challenges associated with prenatal genetic tests
and forming ethical guidelines for their translation into patient care.
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